Among our four defined breast cancer subtypes, the ERBB2-, ER/PR+ subtype showed the best MFS, whereas the ERBB2+, ER/PR- subtype had the worst prognosis (Fig. S2C). This evidence concerns the gene ESR1 and breast carcinoma.